NEWBRY.ST Newbury Pharmaceuticals AB

Healthcare Biotechnology Stockholm Exchange
1.61 SEK
Close of Nov 7, 2026
0.7600 3.47
Market cap
SEK 48.9M
P/E
-
P/B
2.48x
ROE
-116.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Aug 2026.

Is NEWBRY.ST undervalued?

Graham number

The Graham number of Newbury Pharmaceuticals AB cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Newbury Pharmaceuticals AB fundamental analysis

No fundamental analysis for Newbury Pharmaceuticals AB yet.

Newbury Pharmaceuticals AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Newbury Pharmaceuticals AB

Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden and the Scandinavian market. It offers oncology, rare diseases, neurology, and other treatment products. Newbury Pharmaceuticals AB (publ) was incorporated in 2020 and is based in Lund, Sweden.

Full company profile